First Time Loading...

Jubilant Pharmova Ltd
NSE:JUBLPHARMA

Watchlist Manager
Jubilant Pharmova Ltd Logo
Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Watchlist
Price: 742 INR -2%
Updated: Jun 10, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

66.2B
+2%
Revenue
Growth Rates:
1 Year
+8%
3 Years
+9%
5 Years
-26%
7 Years
+13%
10 Years
+17%
3B
+32%
Operating Income
Growth Rates:
1 Year
-30%
3 Years
-73%
5 Years
-79%
7 Years
-70%
10 Years
-59%
378.6m
Net Income
Growth Rates:
1 Year
-61%
3 Years
-96%
5 Years
-95%
7 Years
-91%
10 Years
-

Earnings Waterfall
Jubilant Pharmova Ltd

Revenue
66.2B INR
Cost of Revenue
-21.4B INR
Gross Profit
44.8B INR
Operating Expenses
-41.8B INR
Operating Income
3B INR
Other Expenses
-2.6B INR
Net Income
378.6m INR

Income Statement
Jubilant Pharmova Ltd

Rotate your device to view
Income Statement
Currency: INR
Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
56 381
N/A
58 034
+3%
59 222
+2%
58 560
-1%
58 570
+0%
58 262
-1%
58 381
+0%
59 589
+2%
59 140
-1%
58 933
0%
58 622
-1%
57 896
-1%
58 806
+2%
60 063
+2%
61 484
+2%
63 711
+4%
69 473
+9%
75 578
+9%
80 405
+6%
86 680
+8%
89 773
+4%
91 108
+1%
92 141
+1%
76 520
-17%
67 929
-11%
59 758
-12%
49 500
-17%
58 340
+18%
60 873
+4%
60 985
+0%
65 772
+8%
66 433
+1%
61 825
-7%
61 302
-1%
59 472
-3%
58 892
-1%
61 312
+4%
62 817
+2%
64 169
+2%
64 977
+1%
66 223
+2%
Gross Profit
Cost of Revenue
(23 465)
(26 906)
(25 796)
(26 157)
(26 429)
(29 171)
(25 188)
(24 828)
(23 759)
(25 163)
(21 839)
(21 028)
(21 102)
(23 938)
(22 692)
(23 878)
(26 516)
(31 897)
(30 816)
(33 510)
(34 400)
(38 213)
(34 808)
(25 394)
(20 213)
(16 483)
(9 415)
(14 529)
(15 536)
(17 535)
(16 553)
(16 473)
(14 623)
(17 870)
(15 144)
(15 583)
(17 630)
(22 228)
(20 111)
(20 853)
(21 431)
Gross Profit
32 917
N/A
31 128
-5%
33 427
+7%
32 404
-3%
32 142
-1%
29 091
-9%
33 194
+14%
34 762
+5%
35 382
+2%
33 770
-5%
36 783
+9%
36 869
+0%
37 705
+2%
36 125
-4%
38 793
+7%
39 833
+3%
42 957
+8%
43 681
+2%
49 587
+14%
53 168
+7%
55 371
+4%
52 896
-4%
57 332
+8%
51 125
-11%
47 715
-7%
43 275
-9%
40 086
-7%
43 812
+9%
45 338
+3%
43 451
-4%
49 218
+13%
49 958
+2%
47 200
-6%
43 432
-8%
44 328
+2%
43 310
-2%
43 683
+1%
40 589
-7%
44 058
+9%
44 124
+0%
44 792
+2%
Operating Income
Operating Expenses
(25 760)
(23 847)
(27 084)
(27 658)
(28 119)
(25 079)
(27 356)
(26 833)
(26 172)
(23 761)
(26 766)
(27 247)
(27 803)
(25 355)
(28 547)
(30 023)
(32 387)
(31 697)
(37 710)
(39 954)
(41 497)
(38 969)
(43 723)
(39 026)
(36 358)
(30 888)
(30 346)
(33 522)
(34 349)
(32 008)
(36 848)
(37 838)
(38 039)
(35 187)
(38 475)
(38 606)
(39 472)
(36 577)
(42 015)
(41 877)
(41 827)
Selling, General & Administrative
(14 544)
(20 919)
(15 183)
(15 027)
(14 931)
(22 198)
(14 870)
(14 986)
(14 964)
(20 724)
(14 935)
(14 893)
(15 129)
(22 314)
(15 889)
(16 819)
(18 325)
(28 063)
(21 313)
(22 566)
(23 483)
(34 822)
(24 571)
(21 906)
(20 485)
(27 588)
(18 354)
(19 737)
(19 910)
(28 502)
(20 110)
(20 515)
(20 665)
(31 071)
(20 734)
(20 987)
(21 421)
(32 191)
(21 845)
(21 817)
(21 953)
Depreciation & Amortization
(2 820)
(2 812)
(2 861)
(2 843)
(2 905)
(2 880)
(2 851)
(2 881)
(2 805)
(2 878)
(2 883)
(2 881)
(2 889)
(2 877)
(2 903)
(2 973)
(3 064)
(3 240)
(4 305)
(4 410)
(4 514)
(3 603)
(3 750)
(3 410)
(3 323)
(4 315)
(3 188)
(3 484)
(3 608)
(4 261)
(3 552)
(3 699)
(3 673)
(3 817)
(3 883)
(3 825)
(3 835)
(3 826)
(5 492)
(5 518)
(5 521)
Other Operating Expenses
(8 398)
(116)
(9 041)
(9 790)
(10 283)
0
(9 635)
(8 965)
(8 404)
(159)
(8 949)
(9 473)
(9 785)
(164)
(9 755)
(10 231)
(10 998)
(392)
(12 091)
(12 977)
(13 499)
(544)
(15 401)
(13 709)
(12 549)
1 016
(8 806)
(10 303)
(10 833)
754
(13 185)
(13 623)
(13 699)
(299)
(13 859)
(13 796)
(14 216)
(560)
(14 679)
(14 542)
(14 353)
Operating Income
7 156
N/A
7 281
+2%
6 343
-13%
4 746
-25%
4 023
-15%
4 013
0%
5 838
+45%
7 929
+36%
9 210
+16%
10 009
+9%
10 018
+0%
9 622
-4%
9 903
+3%
10 770
+9%
10 246
-5%
9 812
-4%
10 570
+8%
11 984
+13%
11 878
-1%
13 214
+11%
13 875
+5%
13 926
+0%
13 610
-2%
12 100
-11%
11 357
-6%
12 387
+9%
9 738
-21%
10 288
+6%
10 988
+7%
11 442
+4%
12 370
+8%
12 120
-2%
9 161
-24%
8 245
-10%
5 852
-29%
4 703
-20%
4 210
-10%
4 013
-5%
2 043
-49%
2 247
+10%
2 965
+32%
Pre-Tax Income
Interest Income Expense
(3 297)
(4 575)
(3 248)
(3 378)
(3 485)
(3 317)
(3 683)
(3 638)
(3 565)
(3 789)
(3 633)
(3 518)
(3 612)
(3 056)
(3 277)
(3 137)
(2 926)
(2 478)
(2 883)
(2 850)
(2 762)
(1 933)
(2 197)
(1 883)
(1 688)
(1 553)
(1 750)
(1 902)
(1 909)
(2 157)
(1 696)
(1 592)
(1 463)
(1 921)
(1 510)
(1 596)
(1 753)
(1 342)
(1 991)
(2 115)
(2 174)
Non-Reccuring Items
(3 288)
(701)
(1 220)
328
221
159
(295)
(370)
(396)
(589)
(599)
0
0
(37)
(22)
0
0
(910)
0
0
(62)
(2 908)
(2 908)
(2 908)
(3 175)
(633)
(329)
(329)
(109)
(468)
(212)
(212)
(103)
0
0
(568)
(568)
(2 282)
(568)
0
0
Gain/Loss on Disposition of Assets
0
9
0
0
0
(419)
0
0
0
(90)
0
0
0
(63)
0
0
0
(41)
0
0
0
(46)
0
0
0
0
0
0
0
(67)
0
0
0
(34)
0
0
0
(27)
0
0
0
Total Other Income
249
60
158
382
403
(33)
421
202
170
(119)
139
143
165
(237)
273
295
276
36
427
394
652
0
359
393
135
(72)
316
279
283
(40)
177
187
210
14
187
273
309
(83)
356
324
587
Pre-Tax Income
820
N/A
2 073
+153%
2 031
-2%
2 077
+2%
1 161
-44%
403
-65%
2 282
+466%
4 123
+81%
5 419
+31%
5 422
+0%
5 926
+9%
6 249
+5%
6 458
+3%
7 376
+14%
7 221
-2%
6 969
-3%
7 920
+14%
8 591
+8%
9 423
+10%
10 760
+14%
11 704
+9%
9 038
-23%
8 864
-2%
7 701
-13%
6 628
-14%
10 129
+53%
7 974
-21%
8 336
+5%
9 254
+11%
8 711
-6%
10 640
+22%
10 503
-1%
7 804
-26%
6 304
-19%
4 530
-28%
2 814
-38%
2 199
-22%
278
-87%
(161)
N/A
455
N/A
1 378
+203%
Net Income
Tax Provision
(773)
(696)
(89)
(216)
(906)
(805)
(1 473)
(1 190)
(1 224)
(1 554)
(1 721)
(1 856)
(2 100)
(1 630)
(1 683)
(1 613)
(1 616)
(2 247)
(2 512)
(3 005)
(3 403)
(3 268)
(3 249)
(3 461)
(3 482)
(4 068)
(3 411)
(3 027)
(3 337)
(2 972)
(3 651)
(3 557)
(2 539)
(2 174)
(1 537)
(1 198)
(1 252)
(927)
(896)
(940)
(1 038)
Income from Continuing Operations
48
1 376
1 943
1 861
255
(402)
807
2 932
4 194
3 868
4 204
4 392
4 357
5 746
5 538
5 357
6 304
6 344
6 911
7 754
8 301
5 770
5 616
4 242
3 149
6 060
4 565
5 310
5 917
5 739
6 990
6 947
5 266
4 130
2 993
1 616
948
(649)
(1 056)
(484)
340
Income to Minority Interest
(255)
(286)
(278)
(332)
(271)
(176)
(114)
(33)
46
50
10
5
4
10
69
86
70
84
71
49
(15)
(26)
(47)
(53)
14
0
0
(1)
0
3
3
6
7
9
12
16
18
39
41
39
39
Equity Earnings Affiliates
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Net Income (Common)
(208)
N/A
1 090
N/A
1 664
+53%
1 529
-8%
(17)
N/A
(578)
-3 300%
693
N/A
2 898
+318%
4 240
+46%
3 918
-8%
4 214
+8%
4 396
+4%
4 360
-1%
5 757
+32%
5 606
-3%
5 443
-3%
6 374
+17%
6 428
+1%
6 982
+9%
7 803
+12%
8 286
+6%
5 745
-31%
5 569
-3%
5 959
+7%
5 385
-10%
8 982
+67%
8 013
-11%
7 759
-3%
8 824
+14%
8 359
-5%
9 084
+9%
8 272
-9%
5 683
-31%
4 139
-27%
3 003
-27%
1 630
-46%
963
-41%
(610)
N/A
(1 016)
-67%
(446)
+56%
379
N/A
EPS (Diluted)
-1.3
N/A
6.85
N/A
10.46
+53%
9.61
-8%
-0.11
N/A
-3.63
-3 200%
4.44
N/A
18.57
+318%
27.17
+46%
25.11
-8%
27.03
+8%
28.17
+4%
27.94
-1%
36.91
+32%
35.93
-3%
34.89
-3%
40.85
+17%
41.2
+1%
44.75
+9%
50.01
+12%
53.11
+6%
36.82
-31%
35.02
-5%
37.01
+6%
33.86
-9%
56.49
+67%
50.39
-11%
48.19
-4%
55.49
+15%
52.57
-5%
57.13
+9%
52.02
-9%
35.74
-31%
26.03
-27%
18.87
-28%
10.12
-46%
6.01
-41%
-3.83
N/A
-6.36
-66%
-2.81
+56%
2.38
N/A

See Also

Summary
JUBLPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
JUBLPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JUBLPHARMA stock valuation using valuation multiples.
Wall Street Estimates
JUBLPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JUBLPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 145,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.